W.L. Gore & Associates began paying out the $857.4 million it owes C.R. Bard (NYSE:BCR) for infringing a stent graft patent with a $35.7 million royalty check, according to court documents.
Endoscopic
Israel’s Medigus raises another $7M in support of acid reflux treatment
Israel-based Medigus closed a $7 million funding round, raised through sales of shares and options at about 20¢ apiece (NIS 0.72).
The sale, joined by investors in the U.S. as well as Israel, represents about 21% of the company’s voting power combined with about 17.3 million 3-year options, according to a press release.
Bard prevails again in stent graft patent war with W.L. Gore
Weight loss: USGI launches ambitious study of incision-free bariatric surgery
USGI Medical will enroll up to 350 patients in an FDA-approved clinical trial of the g-Cath EZ suture anchor delivery catheter, an incision-free bariatric surgery technology that has already been used on more than 2,000 patients, mostly in Europe.
Lombard jumps on news of U.K. expansion, focus on Aorfix
Sanovas raises $6.5M Series A1 round
Sanovas raised $6.5 million in a Series A1 round co-founder & CEO Larry Gerrans told MassDevice.com will go toward commercializing its Vas Zeppelin pulmonary device.
Sausalito, Calif.-based Sanovas closed a Series A round last summer consisting entirely of friends and family, Gerrans told us.
Appeals court upholds Medtronic win over Gore in stent graft suit
Afghanistan: Vision-Sciences touts EndoSheath data from field hospital
Vision-Sciences (NSDQ:VSCI) said a small study of its EndoSheath bronchoscopy device in a field hospital in Afghanistan found that the single-use device reduces the risk of cross-contamination and avoids the need for complex sterilization procedures for bronchoscopes.
Lombard treats 1st U.S. patients with Aorfix flexible aortic stent graft
SafeStitch Medical to merge with TransEnterix, raise $30M
SafeStitch Medical (OTC:SFES) and TransEnterix are set to merge next quarter in a deal that includes a private placement worth about $30 million.
LeMaitre graft recall gets FDA’s highest warning
The FDA put its highest-risk Class I label on a recall issued by LeMaitre Vascular (NSDQ:LMAT) over leakage concerns for the Albograft vascular grafts.